ECSP17038893A - Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 - Google Patents
Pirazolpiridinaminas como inhibidores de mknk1 y mknk2Info
- Publication number
- ECSP17038893A ECSP17038893A ECIEPI201738893A ECPI201738893A ECSP17038893A EC SP17038893 A ECSP17038893 A EC SP17038893A EC IEPI201738893 A ECIEPI201738893 A EC IEPI201738893A EC PI201738893 A ECPI201738893 A EC PI201738893A EC SP17038893 A ECSP17038893 A EC SP17038893A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- pyridinamines
- mknk1
- mknk2
- pyrazole
- Prior art date
Links
- 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 title 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 title 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirazolpiridinamina sustituida de fórmula general (I) según se los describe y define aquí, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden a dichos compuestos y el uso de dichos compuestos para elaborar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, enfermedad inflamatoria y enfermedad asociada con dolor inflamatorio, como único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199096 | 2014-12-19 | ||
| EP15187501 | 2015-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17038893A true ECSP17038893A (es) | 2017-07-31 |
Family
ID=54884024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201738893A ECSP17038893A (es) | 2014-12-19 | 2017-06-20 | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10487092B2 (es) |
| EP (1) | EP3233866B1 (es) |
| JP (1) | JP2018501250A (es) |
| KR (1) | KR20170095985A (es) |
| CN (1) | CN107250138A (es) |
| AU (1) | AU2015366417A1 (es) |
| BR (1) | BR112017013148A2 (es) |
| CA (1) | CA2971242A1 (es) |
| CL (1) | CL2017001615A1 (es) |
| CO (1) | CO2017005968A2 (es) |
| CR (1) | CR20170264A (es) |
| CU (1) | CU20170086A7 (es) |
| DO (1) | DOP2017000146A (es) |
| EA (1) | EA201791363A1 (es) |
| EC (1) | ECSP17038893A (es) |
| GT (1) | GT201700138A (es) |
| IL (1) | IL252686A0 (es) |
| MX (1) | MX2017008161A (es) |
| NI (1) | NI201700078A (es) |
| PE (1) | PE20171104A1 (es) |
| PH (1) | PH12017501133A1 (es) |
| SG (1) | SG11201704916TA (es) |
| SV (1) | SV2017005466A (es) |
| TN (1) | TN2017000258A1 (es) |
| TW (1) | TW201625648A (es) |
| UY (1) | UY36460A (es) |
| WO (1) | WO2016096721A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| WO2017081003A1 (en) * | 2015-11-12 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyridinamines |
| MX394700B (es) | 2017-02-14 | 2025-03-24 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. |
| EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| CN111803476A (zh) * | 2020-08-14 | 2020-10-23 | 华中科技大学协和深圳医院 | 芬戈莫德用于抑制革兰阳性细菌活性的用途 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| US20230000986A1 (en) * | 2021-07-01 | 2023-01-05 | Board Of Regents, The University Of Texas System | Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| CA2530281C (en) * | 2003-07-24 | 2013-02-12 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
| JP5070053B2 (ja) * | 2004-08-20 | 2012-11-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 新規な複素環 |
| EP2663312B1 (en) * | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA2873967A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
| EP2852596B1 (en) * | 2012-05-21 | 2016-06-22 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
| US9546153B2 (en) * | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| CA2899665A1 (en) | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted thienopyrimidines and pharmaceutical use thereof |
-
2015
- 2015-12-14 SG SG11201704916TA patent/SG11201704916TA/en unknown
- 2015-12-14 KR KR1020177019615A patent/KR20170095985A/ko not_active Withdrawn
- 2015-12-14 BR BR112017013148-0A patent/BR112017013148A2/pt not_active IP Right Cessation
- 2015-12-14 CR CR20170264A patent/CR20170264A/es unknown
- 2015-12-14 TN TN2017000258A patent/TN2017000258A1/en unknown
- 2015-12-14 PE PE2017001100A patent/PE20171104A1/es not_active Application Discontinuation
- 2015-12-14 WO PCT/EP2015/079587 patent/WO2016096721A1/en not_active Ceased
- 2015-12-14 CA CA2971242A patent/CA2971242A1/en active Pending
- 2015-12-14 CN CN201580076266.7A patent/CN107250138A/zh active Pending
- 2015-12-14 CU CUP2017000086A patent/CU20170086A7/es unknown
- 2015-12-14 MX MX2017008161A patent/MX2017008161A/es unknown
- 2015-12-14 US US15/537,694 patent/US10487092B2/en active Active
- 2015-12-14 JP JP2017533275A patent/JP2018501250A/ja active Pending
- 2015-12-14 EP EP15813014.6A patent/EP3233866B1/en active Active
- 2015-12-14 AU AU2015366417A patent/AU2015366417A1/en not_active Abandoned
- 2015-12-14 EA EA201791363A patent/EA201791363A1/ru unknown
- 2015-12-18 TW TW104142845A patent/TW201625648A/zh unknown
- 2015-12-18 UY UY0001036460A patent/UY36460A/es not_active Application Discontinuation
-
2017
- 2017-06-05 IL IL252686A patent/IL252686A0/en unknown
- 2017-06-16 CO CONC2017/0005968A patent/CO2017005968A2/es unknown
- 2017-06-16 PH PH12017501133A patent/PH12017501133A1/en unknown
- 2017-06-19 DO DO2017000146A patent/DOP2017000146A/es unknown
- 2017-06-19 CL CL2017001615A patent/CL2017001615A1/es unknown
- 2017-06-19 GT GT201700138A patent/GT201700138A/es unknown
- 2017-06-19 NI NI201700078A patent/NI201700078A/es unknown
- 2017-06-19 SV SV2017005466A patent/SV2017005466A/es unknown
- 2017-06-20 EC ECIEPI201738893A patent/ECSP17038893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10487092B2 (en) | 2019-11-26 |
| JP2018501250A (ja) | 2018-01-18 |
| CO2017005968A2 (es) | 2017-10-20 |
| SG11201704916TA (en) | 2017-07-28 |
| TN2017000258A1 (en) | 2018-10-19 |
| KR20170095985A (ko) | 2017-08-23 |
| TW201625648A (zh) | 2016-07-16 |
| CL2017001615A1 (es) | 2018-03-16 |
| AU2015366417A1 (en) | 2017-06-29 |
| DOP2017000146A (es) | 2017-07-31 |
| CR20170264A (es) | 2017-07-21 |
| PE20171104A1 (es) | 2017-08-07 |
| EP3233866A1 (en) | 2017-10-25 |
| UY36460A (es) | 2016-07-29 |
| WO2016096721A1 (en) | 2016-06-23 |
| NI201700078A (es) | 2017-09-22 |
| CN107250138A (zh) | 2017-10-13 |
| SV2017005466A (es) | 2018-10-02 |
| EP3233866B1 (en) | 2021-04-21 |
| EA201791363A1 (ru) | 2018-01-31 |
| US20180162877A1 (en) | 2018-06-14 |
| GT201700138A (es) | 2018-12-06 |
| BR112017013148A2 (pt) | 2019-11-19 |
| CA2971242A1 (en) | 2016-06-23 |
| PH12017501133A1 (en) | 2017-11-27 |
| CU20170086A7 (es) | 2017-11-07 |
| MX2017008161A (es) | 2017-09-18 |
| IL252686A0 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| NI201700078A (es) | Pirazolpiridinaminas | |
| UY33598A (es) | Imidazopiridazinas sustituidas | |
| UY36422A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| MX2015011316A (es) | Imidazopiridazinas sustituidas. | |
| NI201600006A (es) | Pirazolo-piridinaminas sustituidas | |
| CR20160433A (es) | Nuevos compuestos | |
| CU20160072A7 (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| UY37444A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| UY37032A (es) | Compuestos de heteroarilbenzimidazol | |
| AR094934A1 (es) | Imidazopiridazinas sustituidas | |
| UY34630A (es) | Imidazopiridazinas sustituidas con amino |